NOxygen Therapeutics, Inc.

Biotechnology ResearchMichigan, United States2-10 Employees

NOxygen Therapeutics, Inc. is a biotechnology research company headquartered in Ann Arbor, Michigan, focused on advanced wound care. It is developing NOxyCure, a nitric oxide–based platform intended to treat chronic wounds such as diabetic foot ulcers, venous leg ulcers, and surgical site infections. NOxyCure delivers nitric oxide directly to the wound bed in a controlled, two-stage protocol that first provides a high antimicrobial burst and biofilm disruption, then a sustained dose to promote healing over about two to three days. The company is expanding its core team and pursuing a Series round of funding while engaging with potential corporate partners for manufacturing and distribution. Public clinical evidence from the ProNOx1 randomized controlled trial indicated an 88.6% wound area reduction versus 46.9% with standard care and outcomes eight weeks faster, with estimated cost savings per patient between $10,000 and $14,000. The organization has a small workforce of 2–10 employees and operates from 600 South Wagner Road, Suite 6, Ann Arbor, MI 48103, United States.

Sign up for free to view info

Email Format Employee directory